A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in bone tissue, offering a potential new treatment target for patients with ...
Xtandi addition to ADT and radiation did not significantly improve MFS in the overall high-risk prostate cancer population. Patients with clinical N1 disease showed improved five-year MFS with Xtandi, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback